alexa Statin Therapy - Is Hypogonadism a Cause for Concern? | OMICS International
ISSN: 2161-1017
Endocrinology & Metabolic Syndrome
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Statin Therapy - Is Hypogonadism a Cause for Concern?

Sheriff DS*

Department of Biochemistry, Benghazi University, Benghazi, Libya

Corresponding Author:
Sheriff DS
Department of Biochemistry
Benghazi University, Benghazi, Libya
Tel: +218 61 2233010
E-mail: [email protected]

Received Date: November 02, 2015; Accepted Date: November 05, 2015; Published Date: November 09, 2015

Citation:Sheriff DS (2015) Statin Therapy - Is Hypogonadism a Cause for Concern?. Endocrinol Metab Syndr 4:208. doi:10.4172/2161-1017.1000208

Copyright: © 2015 Sheriff DS. et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Endocrinology & Metabolic Syndrome

The isoprenoids form one of the largest families of naturally occurring compounds [1]. In Figure 1 metabolic map of the isoprene metabolism is depicted [2]. The biosynthesis of these isoprenoids starts from two common precursors, Isopentenyl Diphosphate (IPP) and its isomer Dimethylallyl Diphosphate (DMAPP). After the synthesis of IPP and DMAPP, which in eukaryotes are synthesised via the mevalonate pathway, [3] the enzyme Geranyl Pyrophosphate Synthase (GPP synthase) catalyses the head-to-tail addition of IPP to DMAPP yielding Geranyl Pyrophosphate (GPP).

endocrinology-metabolic-syndrome-Biochemical-pathway

Figure 1: Biochemical pathway of isoprene metabolism

Condensation of GPP with IPP by farnesyl pyrophosphate synthase affords farnesyl pyrophosphate and subsequent condensation of FPP with IPP by GPP synthase affords geranylgeranyl pyrophosphate (GGPP) [4,5]. The isoprenoids FPP and GGPP are the key intermediates from which most isoprene metabolism products are derived.

Drug Development and the Mevalonate Pathway

Interference in the mevalonate pathway is an attractive and rewarding approach for the development of drugs toward several pathological disorders that are related to isoprenoid functioning. The most important is the development of cholesterol lowering agents.

Cholesterol Lowering Agents

An important approach toward the treatment of elevated cholesterol levels in the blood plasma involves inhibition of cholesterol biosynthesis. Well known examples are the statins 5ab compounds that act by inhibiting HMG-CoA reductase (Figures 2 and 3). As HMG-CoA reductase is situated early in the biochemical pathway, obstruction of this enzyme also influences the biosynthesis of other important products of the isoprene pathway.

endocrinology-metabolic-syndrome-simplified-representation

Figure 2: A simplified representation of the IPP and DMAPP biosynthesis via the mevalonate pathway and their further processing (ATP=adenosine triphosphate, ADP=adenosine diphosphate

endocrinology-metabolic-syndrome-reductase-inhibitors

Figure 3: Examples of statins as HMG-CoA reductase inhibitors: lovastatin (Mevacor→), simvastatin (Zocor→), pravastatin (Lipostat→), fluvastatin (Lescol→) and atorvastatin5cd (Lipitor→).

The introduction of statin therapy had a major positive effect in lowering serum cholesterol levels and therefore a marked reduction in cases with hypercholesterolemia and Coronary Artery Disease (CAD) [6]. Holistic approach to the treatment of well- being of the patient led to the observation that statin therapy is associated with hypogonadism [7]. The finding of hypogonadism has resulted in reviewing statin therapy and has cautioned the physician to use statins judiciously. Therefore, there is a need of introspecting the use of drugs we use for therapy and its possible adverse effects. It has necessitated the need to balance the beneficial as well as possible adverse effects of pharmacotherapy in question.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 8090
  • [From(publication date):
    December-2015 - Dec 11, 2017]
  • Breakdown by view type
  • HTML page views : 8018
  • PDF downloads : 72
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version